A prospective randomized trial of two 14-day sequential therapies for Helicobacter pylori eradication

被引：0
|
作者：
Chang, S-N [1 ,2 ]
Wu, D-C [3 ]
Wu, J-Y [3 ]
Lai, K-H [1 ,2 ]
Hsu, P-I [1 ,2 ]
机构：
[1] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan
[2] Natl Yang Ming Univ, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A20 / A20
页数：1
相关论文
共 50 条
  • [41] Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
    Huang, Hsiang Tso
    Wang, Hsin-Ming
    Yang, Shih-Cheng
    Tai, Wei-Chen
    Liang, Chih-Ming
    Wu, Keng-Liang
    Lee, Chen-Hsiang
    Chuah, Seng-Kee
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 2073 - 2080
  • [42] High efficacy of 7-day and 14-day vonoprazan-based quadruple therapy for Helicobacter pylori eradication in areas with high clarithromycin resistance: A prospective randomized study (VQ-HP trial)
    Tungtrongchitr, N.
    Pornthisarn, B.
    Cholprasertsuk, S.
    Siramolpiwat, S.
    Bhanthumkomol, P.
    Nunanun, P.
    Issariyakulkarn, N.
    Eiamsitrakoon, T.
    Mahachai, V.
    Vilaichone, R. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 36 - 36
  • [43] Search for a Grade a Therapy for Helicobacter pylori Infection: 14-Day Sequential or Sequential-Concomitant Hybrid Therapy
    Hsu, Ping-I
    Wu, Deng-Chyang
    Wu, Jeng-Yih
    Graham, David Y.
    GASTROENTEROLOGY, 2010, 138 (05) : S111 - S111
  • [44] Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC):: A randomized comparison between two 7-day triple therapies and a 14-day dual therapy
    de Boer, WA
    Haeck, PWE
    Otten, MH
    Mulder, CJJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (07): : 1101 - 1107
  • [45] 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial
    Amiot, Aurelien
    Hacoon, Jeremy
    Heluwaert, Frederic
    Mion, Francois
    Lamarque, Dominique
    Moussata, Driffa
    Mimouni, Maroua
    Delchier, Jean-Charles
    Durand-Zaleski, Isabelle
    Audureau, Etienne
    Bastuji-Garin, Sylvie
    HELICOBACTER, 2024, 29 (02)
  • [46] Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea
    Kim, Seung Young
    Lee, Sang Woo
    Choe, Jung Wan
    Jung, Sung Woo
    Hyun, Jong Jin
    Jung, Young Kul
    Koo, Ja Seol
    Yim, Hyung Joon
    HELICOBACTER, 2017, 22 (06)
  • [47] Standard triple and sequential therapies for Helicobacter pylori eradication: An update
    Zullo, Angelo
    Hassan, Cesare
    Ridola, Lorenzo
    De Francesco, Vincenzo
    Vaira, Dino
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2013, 24 (01) : 16 - 19
  • [48] Search for a Grade A therapy for H. pylori eradication: 14-day sequential or sequential-concomitant hybrid therapy
    Hsu, P.
    Wu, D.
    Wu, J.
    Graham, D.
    HELICOBACTER, 2010, 15 (04) : 314 - 314
  • [49] Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by 'geographical weighting'
    Losurdo, G.
    Leandro, G.
    Principi, M.
    Giorgio, F.
    Montenegro, L.
    Sorrentino, C.
    Ierardi, E.
    Di Leo, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (10) : 1112 - 1120
  • [50] BOTH 14-DAY REVERSE HYBRID AND CONCOMITANT THERAPIES CURE MOST PATIENTS WITH HELICOBACTER PYLORI INFECTION IN POPULATIONS WITH MODERATE ANTIBIOTIC RESISTANE: A RANDOMIZED CONTROLLED TRIAL
    Hsu, Ping-I
    Wu, Deng-Chyang
    GASTROENTEROLOGY, 2018, 154 (06) : S17 - S17
12345